贝伐单抗在青光眼滤过性手术应用的研究进展

滤过泡瘢痕化是导致青光眼滤过性手术失败的主要因素，目前研究已证实血管内皮生长因子（vascularendothelialgrowthfactor，VEGF）在促进血管生成、创伤愈合、瘢痕形成中起重要作用。近年来眼科学者将VEGF抑制剂贝伐单抗（bevacizumab）作为抗瘢痕形成辅助用药用于青光眼滤过性手术，证实其对促进功能性滤过泡形成、控制眼压有较好的疗效，从而提高了手术成功率。本文就贝伐单抗在青光眼滤过性手术中的基础研究和临床应用等方面的研究进展作一综述。（国际眼科纵览，2012，36：298—301）

Bevacizumab application in glaucoma filtering surgery

Filtering bleb scarring is the main determinant factor leading to the failure of glaucoma filtering surgery. The vascular endothelial growth factor （VEGF） has been proved to be a significant role in the process of angiogenesis, wound healing and scar formation. In recent years, ophthalmologists have ap- plied VEGF inhibitor bevacizumab to glaucoma filtering surgery as an adjunct for inhibiting postoperative scarring, which shows good effect to promote the functioning bleb formation, control the intraocular pressure, thereby improve surgical outcome. This article reviewed the experimental study and clinical application of VEGF inhibitor bevacizumab in glaucoma filtering surgery. （Int Rev Ophthalmol, 2012, 36：298-301 ）